Skip to content

The effect of nifedipine and indomethacin on pregnant women

The effect of nifedipine and indomethacin on the number of uterine contractions, CRP and white blood cell count in pregnant women with idiopathic preterm labor

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220219054064N1
Enrollment
64
Registered
2022-03-06
Start date
2022-02-25
Completion date
Unknown
Last updated
2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Differences in the number of white blood cells. Condition 2: Elevated C-reactive protein (CRP). Other disorders of white blood cells Elevated C-reactive protein (CRP)

Interventions

Intervention 1: Intervention group: In the indomethacin group (n = 32), 50-mg oral capsules will be administered as the initial dose and then every 50 mg oral capsule every 8 hours for 48 hours, and t

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 26-34 weeks gestational age confirmed by NLO and first trimester ultrasound Contractions of four numbers in 20 minutes or eight in 60 minutes Cervical dilatation equal to or more than 1 cm and cervical effusion 50% or more

Exclusion criteria

Exclusion criteria: Inflammatory diseases, autoimmune, infectious, multiple, hypertension, diabetes, cervical insufficiency, bladder rupture, vaginal bleeding, fetal death or fetal malignancy, KWFT, history of trauma, cirrhosis, dilatation, cirrhosis Maternal, known uterine abnormalities (with a history or ultrasound), smoking history, history of taking any medication other than the usual supplements during pregnancy, tuberculosis, intrauterine polycystic ovary syndrome, ulcerative colitis Maternal and fetal HJT, previous tocolytic use in the same pregnancy and mothers for whom continuing pregnancy for medical reasons is dangerous and blood pressure less than 50.90 mm Hg

Design outcomes

Primary

MeasureTime frame
Reactive Protein Test. Timepoint: The measurement is performed on the first day after delivery. Method of measurement: Blood test and use of photometric analyzer.;Number of uterine contractions. Timepoint: In the first 2 hours after administration of the drug, it will be checked every 15 minutes and if controlled, every 4-6 hours. Method of measurement: See the number of contractions.;Number of white blood cells. Timepoint: The first day after delivery. Method of measurement: CBC DIFF.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactErfan zarhe

Yasouj University of Medical Sciences

lahze007@gmail.com+98 74 1333 7251

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026